Hospital Acquired Disease Testing Market Research Report by Product, End User and Forecast 2023

Global Hospital Acquired Disease Testing Market Insights

The rising incidence of hospital acquired infections (HAIs) has emerged as a major concern for governments, particularly across developing and underdeveloped countries. In first world countries such as the U.S., various regulations are in place for penalizing hospitals exhibiting a high incidence of HAIs. Such regulations augur well for the hospital acquired disease testing market in developed countries. In contrast, the absence of proper regulations and stringent policies limiting the adoption of molecular-biology-based diagnostics are restricting the expansion of the market across emerging nations.

Nevertheless, Transparency Market Research (TMR) forecasts the market to gain considerable momentum in the forthcoming years with the advent of the latest technologies. As per TMR, the global hospital acquired disease testing market stood at US$416.7 mn in 2014. Exhibiting a CAGR of 19.9% CAGR between 2015 and 2023, the market is expected to reach US$2.07 bn by the end of 2023.

Browse full report on Hospital Acquired Disease Testing Market -

http://www.transparencymarketresearch.com/hospital-acquired-disease-testing.html

Demand from Asia Pacific to Surge as the Region Witness High Incidence of HAIs

Regionally, Europe, Asia Pacific, North America, and Rest of the World constitute the key markets for hospital acquired disease testing. Among these regions, North America held a dominant share of 38.5% in the market in 2014. Europe, in the same year, emerged as the second-largest market with a share of 21.6%. With over a million people suffering from hospital acquired infection, leading to several deaths every year, the U.S. emerged as the largest market for hospital acquired disease testing in North America.

Other than the rising demand from the diagnostic market, the latest advancements in molecular diagnostics have been propelling the market in the region. Favorable regulations implemented to prevent the prevalence of HAIs also support the market’s growth in North America.

TMR forecasts Asia Pacific to exhibit the fastest growth for hospital acquired disease testing. The incidence of nosocomial infections is considerably high in the region. Moreover, Asia Pacific also has stringent regulations in place aimed at curbing HAIs. This, combined with the rising investment in the healthcare infrastructure, is a primary contributor to the hospital acquired disease testing market in the region. The Asia Pacific market is expected to surge at the highest CAGR of 21.2% between 2015 and 2023.

Increasing Incidence of Urinary Tract Infections Fuels Demand for Hospital Acquired Disease Testing

Urinary tract infection is one of the most common hospital acquired infections affecting millions around the world. It has therefore emerged as the largest segment in the global hospital acquired disease testing market, based on test type. As per TMR, the segment was valued at US$155.3 mn in 2014. Rising at a CAGR of 19.8%, the urinary tract infection testing segment is forecast to reach 768.8 mn in 2023.

Apart from this, the demand for hospital acquired disease testing will also rise in response to the increasing incidence of surgical site infection, pneumonia, and MRSA, which is considered the fastest growing HAI in the world. Hospital acquired disease testing is also used for the bloodstream test.

Some of the leading players operating in the global hospital acquired disease testing market are L Hoffman La Roche, Gen-Probe Inc., Diatherix Laboratories Inc., Life Technologies Corporation, Qiagen GmbH, Cantel Medical Corporation, Nordion, Inc., Cepheid, Inc., Meridian Biosciences, and others.

Request for sample of this report -

http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1759

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

This release was published on openPR.